Edition:
India

Medivir AB (MVIRb.ST)

MVIRb.ST on Stockholm Stock Exchange

44.00SEK
23 Jan 2018
Change (% chg)

-- (--)
Prev Close
44.00kr
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
72,912
52-wk High
92.00kr
52-wk Low
43.05kr

Select another date:

Mon, Jan 8 2018

BRIEF-Medivir: successful completion of pre-clinical safety studies with MIV-818

* SUCCESSFUL COMPLETION OF PRE-CLINICAL SAFETY STUDIES WITH MIV-818, ENABLING START OF PHASE I CLINICAL STUDIES IN 2018 Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

BRIEF-Medivir announces new cancer project

* Medivir announces new cancer project, Leukotide, derived from its in-house nucleotide platform

BRIEF-Medivir Q3 EBITDA loss widens

* Says ‍net turnover for continuing operations totalled SEK 5.1 million (25.7 m), SEK 5.1 million (13.5 m) of which comprised Q3's royalties​

BRIEF-Medivir receives FDA fast track designation for MIV-711 for treatment of OA

* Medivir receives FDA fast track designation for MIV-711 for the treatment of OA Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

BRIEF-Medivir says positive top line data from 6-month initial phase IIa study of MIV-711

* Announces positive top line data from MIV-711-201, 6-month initial phase IIa study of MIV-711 in moderate knee osteoarthritis patients Source text for Eikon: Further company coverage:

BRIEF-Medivir: Janssen discontinues development of JNJ-4178 for hepatitis C

* Medivir announces Janssen to discontinue development of JNJ-4178 for hepatitis C

BRIEF-Medivir initiates clinical study of birinapant in combination with keytruda in patients with treatment-refractory solid tumours

* Medivir initiates clinical study of birinapant in combination with keytruda® (pembrolizumab) in patients with treatment-refractory solid tumours Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

BRIEF-Medivir Q2 EBITDA loss widens

* Says net turnover for continuing operations totalled SEK 9.5 million (36.9 m), SEK 7.7 million (24.2 m) of which comprised Q2's royalties for simeprevir

Select another date: